FDA: Safety update on TNF- antagonists: Infliximab and etanercept
Arthritis Advisory Committee Meeting (August 17), Food and Drug Administration, Center for Biologics Evaluation and Research
FDA: Safety update on TNF- antagonists: infliximab and etanercept. Arthritis Advisory Committee Meeting (August 17), Food and Drug Administration, Center for Biologics Evaluation and Research, 2001.
(2001)
2
0242410494
Infections and anti-tumor necrosis factor alpha therapy
ELLERIN T, RUBIN RH et al.: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22.
Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis
(in Spanish)
BAIXAULI RUBIO A, RODRIGUEZ GORRIZ E et al.: [Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis]. An Med Interna 2003; 20: 276-7 (in Spanish).
Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection
BELOSEVIC M, DAVIS C et al.: Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. J Immunol 1988; 141: 890-6.
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha
GREEN S, CRAWFORD R et al.: Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol 1990; 145: 4290-7.
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism
GREEN S, MELTZER M et al.: Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990; 144: 278-83.
